Ligand Pharmaceuticals Inc (LGND)
80.36
+7.14
(+9.75%)
USD |
NASDAQ |
May 08, 16:00
80.30
-0.06
(-0.07%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value: 1.133B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 1.133B |
| May 07, 2024 | 1.005B |
| May 06, 2024 | 997.70M |
| May 03, 2024 | 1.017B |
| May 02, 2024 | 988.16M |
| May 01, 2024 | 972.00M |
| April 30, 2024 | 944.52M |
| April 29, 2024 | 954.76M |
| April 26, 2024 | 956.73M |
| April 25, 2024 | 953.14M |
| April 24, 2024 | 964.45M |
| April 23, 2024 | 944.52M |
| April 22, 2024 | 920.10M |
| April 19, 2024 | 990.85M |
| April 18, 2024 | 989.26M |
| April 17, 2024 | 1.103B |
| April 16, 2024 | 1.122B |
| April 15, 2024 | 1.119B |
| April 12, 2024 | 1.148B |
| April 11, 2024 | 1.149B |
| April 10, 2024 | 1.137B |
| April 09, 2024 | 1.150B |
| April 08, 2024 | 1.116B |
| April 05, 2024 | 1.087B |
| April 04, 2024 | 1.087B |
| Date | Value |
|---|---|
| April 03, 2024 | 1.029B |
| April 02, 2024 | 1.002B |
| April 01, 2024 | 1.009B |
| March 31, 2024 | 999.65M |
| March 28, 2024 | 1.124B |
| March 27, 2024 | 1.092B |
| March 26, 2024 | 1.045B |
| March 25, 2024 | 1.056B |
| March 22, 2024 | 1.087B |
| March 21, 2024 | 1.121B |
| March 20, 2024 | 1.124B |
| March 19, 2024 | 1.108B |
| March 18, 2024 | 1.107B |
| March 15, 2024 | 1.088B |
| March 14, 2024 | 1.103B |
| March 13, 2024 | 1.118B |
| March 12, 2024 | 1.111B |
| March 11, 2024 | 1.109B |
| March 08, 2024 | 1.136B |
| March 07, 2024 | 1.113B |
| March 06, 2024 | 1.117B |
| March 05, 2024 | 1.140B |
| March 04, 2024 | 1.180B |
| March 01, 2024 | 1.223B |
| February 29, 2024 | 1.235B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
615.03M
Minimum
Mar 16 2020
3.502B
Maximum
Feb 09 2021
1.462B
Average
1.323B
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.472B |
| ADMA Biologics Inc | 1.645B |
| Viking Therapeutics Inc | 7.849B |
| Voyager Therapeutics Inc | 235.23M |
| Palatin Technologies Inc | 23.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 86.14M |
| Revenue (Quarterly) | 30.98M |
| Total Expenses (Quarterly) | 27.99M |
| EPS Diluted (Quarterly) | 4.75 |
| Gross Profit Margin (Quarterly) | 90.70% |
| Profit Margin (Quarterly) | 64.72% |
| Earnings Yield | 6.62% |
| Normalized Earnings Yield | 0.3972 |